Unknown

Dataset Information

0

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.


ABSTRACT: During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2 (HER-2) positive breast cancer. Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food and drug administration (FDA)-approved for the treatment of breast cancer patients with HER-2 over-expressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic updates that succinctly recapitulate what we have learnt over these last years and help us to apply that information in our daily practice. This review will pursue that objective. We will summarize the most relevant and updated information related to the state of the art management of HER-2 positive breast cancer in all the clinical scenarios including the adjuvant, neoadjuvant and metastatic settings. But we will also critically appraise that literature in order to highlight some key clinical concepts that should not be overlooked. Lastly, this review will also point out some of the most promising strategies that are currently being tested and may soon become available.

SUBMITTER: Recondo G 

PROVIDER: S-EPMC4127614 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.

Recondo Gonzalo G   Dìaz Canton Enrique E   de la Vega Màximo M   Greco Martin M   Recondo Gonzalo G   Valsecchi Matias E ME  

World journal of clinical oncology 20140801 3


During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2 (HER-2) positive breast cancer. Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food and drug administration (FDA)-approved for the treatment of breast cancer patients with HER-2 over-expressed. However, given the amount of information gathered from years of uninterrupted clinical research, it is essential to have periodic  ...[more]

Similar Datasets

| S-EPMC9320771 | biostudies-literature
| S-EPMC6799843 | biostudies-literature
| S-EPMC9640784 | biostudies-literature
| S-EPMC3270265 | biostudies-other
| S-EPMC7959316 | biostudies-literature
| S-EPMC2819039 | biostudies-other
| S-EPMC6310352 | biostudies-other
| S-EPMC3835685 | biostudies-literature
| S-EPMC7522523 | biostudies-literature
| S-EPMC6457207 | biostudies-literature